Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.57 |
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247653 | 0.90 | ALDH1A1 (0.61) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL17512408 | 0.88 | MAPT (0.51) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL17507532 | 0.88 | ALDH1A1 (0.68) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL17512436 | 0.88 | MAPT (0.53) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL3245109 | 0.87 | ALDH1A1 (0.60) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL17512406 | 0.86 | MAPT (0.49) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL7149932 | 0.86 | CPT2 (0.64) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL22966721 | 0.84 | MAPT (0.61) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL19034468 | 0.84 | NPC1 (0.61) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL3241519 | 0.84 | ALDH1A1 (0.58) | MEN1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | claimed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| WO-2021026257-A1 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | EMPIRICO INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2016029136-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | WO | disclosed |
| US-6528528-B2 | Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | disclosed |
| US-6268387-B1 | INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | L3MBTL3, AFG3L2, AMPD3 | MEN1 3177/4885KMT2A 2505/4885MAPT 4742/4885 |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | TPMT, CTH, CBS | MEN1 3193/4885KMT2A 1976/4885MAPT 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.